Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

TG Therapeutics' financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

S&P 500 members Intercontinental Exchange and Allstate lead this weekend's watch list of five stocks near buy points, showing ...

Kesimpta Market Report 2025 The Business Research Company's Key Market Driver In Kesimpta Industry 2025: Increasing Multiple Sclerosis Prev ...

We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...

TG Therapeutics stock skyrocketed Monday after easily beating fourth-quarter sales expectations and issuing a bullish outlook for 2025.

What is Kesimpta for MS? Kesimpta (ofatumumab) is an anti-CD20 antibody approved for the treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Sales growth was primarily driven by heart failure drug Entresto, arthritis treatment Cosentyx, multiple sclerosis drug Kesimpta and breast cancer drug Kisqali. Novartis also released the aggregated ...